Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL001 in metastatic or recurrent melanoma
2024-513062-19-00Phase 2Completed
- Sponsor
- Achilles Therapeutics plc
- Start
- May 2024
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of ATL001 in melanoma (2 arms), sponsored by Achilles Therapeutics plc. Primary endpoint: Safety and tolerability. Started May 2024; status: completed.
02
Drugs
ATL001
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-513062-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513062-19-00.